Digital Look

Welcome to Digital Look++,
you are not logged in

Theracryf (TCF)

Pharma and Biotech

0.23p

Select chart: EPS | Dividend | Revenue

Period Ending	Period	Revenue (£m)	Pre-tax (£m)	EPS	Dividend
30-Sep-24	Interim	n/a	(1.25)	(29.00)p	n/a

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Mar-20	n/a	(3.17)	(2.07)p	n/a	n/a	n/a	n/a	0.0%
31-Mar-21	0.19	(3.21)	(1.82)p	n/a	n/a	n/a	n/a	0.0%
31-Mar-22	n/a	(3.17)	(0.99)p	n/a	n/a	n/a	n/a	0.0%
31-Mar-23	0.44	(5.01)	1.47p	2.5	n/a	n/a	n/a	0.0%
31-Mar-24	0.40	(3.57)	(1.14)p	n/a	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Forecasts data is not available for this company.

	5 Yr High	5 Yr Low	5 Yr Avg	Curr / Avg
Latest	2.52	n/a	n/a	0

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

Find out about IFRS and how this affects the financial infomation for all UK companies.